COVID-19疫苗分配中SARS-CoV-2特异性抗体检测的意义
结果显示,在疫苗供应有限时,先做抗体检测再分配疫苗可降低感染率和死亡,且效果取决于疫苗可用时间与感染高峰的相对时机。
要点
- 抗体检测优先分配可降低感染率和死亡。
- 效果取决于疫苗可用时间与感染高峰的相对时机。
- 高峰前及接近高峰时部署疫苗,病例和死亡降幅最大。
核心结论
- 将抗体检测纳入接种计划是最大化COVID-19疫苗效益的有效方法。
- 决策者需考虑感染高峰日与疫苗可用时间的相对时机。
研究设计与样本
- 采用扩展的易感-感染-康复(SIR) compartmental模型模拟COVID-19传播。
- 建模4种大流行严重程度场景及疫苗在大流行期间可用的不同时间。
- 符合条件个体在接种前接受抗体检测的概率p为0、0.25、0.5、0.75和1。
- 疫苗建模为单剂疫苗,效力为90%和70%。
主要发现
- 使用抗体检测优先分配有限疫苗可降低感染率和死亡。
- 降低幅度取决于疫苗可用时间相对于感染高峰日。
- 病例和死亡的最大百分比降幅发生在疫苗部署于感染高峰日之前且接近高峰日时。
- 疫苗部署延迟时,病例和死亡数的减少幅度减小。
临床怎么用
- 在疫苗供应有限时,可考虑将抗体检测作为分配计划的组成部分以优先接种易感个体。
- 决策者应评估疫苗可用时间与感染高峰日的相对时机以优化接种策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the value of using SARS-CoV-2 specific antibody testing to prioritize the vaccination of susceptible individuals as part of a COVID-19 vaccine distribution plan when vaccine supply is limited. METHODS: An extended susceptible-infected-recovered (SIR) compartmental model was used to simulate COVID-19 spread when considering diagnosis, isolation, and vaccination of a cohort of 1 million individuals. The scenarios modeled represented 4 pandemic severity scenarios and various times when the vaccine becomes available during the pandemic. Eligible individuals have a probability p of receiving antibody testing prior to vaccination (p = 0, 0.25, 0.5, 0.75, and 1). The vaccine was modeled as a single dose vaccine with 90% and 70% efficacy. The value of serology testing was evaluated by comparing the infection attack rate, peak infections, peak day, and deaths. RESULTS: The use of antibody testing to prioritize the allocation of limited vaccines reduces infection attack rates and deaths. The size of the reduction depends on when the vaccine becomes available relative to the infection peak day. The largest percentage reduction in cases and deaths occurs when the vaccine is deployed before and close to the infection peak day. The reduction in the number of cases and deaths diminishes as vaccine deployment is delayed. CONCLUSIONS: Antibody testing as part of the vaccination plan is an effective method to maximize the benefit of a COVID-19 vaccine. Decision-makers need to consider relative timing between the infection peak day and when the vaccine becomes available.
引用
- Fujimoto AB, Keskinocak P, Yildirim I, et al. Significance of SARS-CoV-2 specific antibody testing during COVID-19 vaccine allocation. Vaccine. 2021. PMID: 34274126. doi:10.1016/j.vaccine.2021.06.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。